Natco Pharma’s Vizag formulation facility gets USFDA approval

28 Apr 2020 Evaluate
Natco Pharma has received final approval for its 1st supplemental Abbreviated New Drug Application (sANDA) product from the US Food and Drug Administration (US FDA) filed from its new drug formulations facility in Vizag, Andhra Pradesh.
 
The sANDA, submitted as 'Prior Approval Supplement,' provides for company’s Vizag facility as an alternate site for manufacture of the approved drug product for the US market.

Natco Pharma was promoted as a private company to be in the business of research, developing, manufacturing and marketing of pharmaceutical substances and finished dosage forms for Indian and International markets.

Natco Pharma Share Price

917.90 3.05 (0.33%)
19-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1745.10
Dr. Reddys Lab 1278.90
Cipla 1517.00
Zydus Lifesciences 919.85
Lupin 2125.70
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×